医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

pembrolizumab

Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma

Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: and Radically Unresectable Urothelial Carcinoma Merck’s KEYTRUDA NSCLC pembrolizumab Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma

2024年09月25日

GI Innovation Announces New Clinical Trial Collaboration and Supply Agreement to Evaluate GI-102 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Immunotherapy-Resistant Liver Cancer, Melanoma, and Renal Cell Carcinoma

GI Innovation Announces New Clinical Trial Collaboration and Supply Agreement to Evaluate GI-102 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Immunotherapy-Resistant Liver Cancer, Melanoma, and Renal Cell Carcinoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Melanoma pembrolizumab

2024年08月26日

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Enfortumab Vedotin European Medicines Agency Validates Type II Variation Application for PADCEV for First-Line Treatment of Advanced Bladder Cancer pembrolizumab with KEYTRUDA

2024年01月27日

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv PADCEV pembrolizumab to Treat Advanced Bladder Cancer with KEYTRUDA

2023年12月16日

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv for First-Line Treatment of Advanced Bladder Cancer pembrolizumab sBLA with KEYTRUDA

2023年12月01日

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: and KEYTRUDA enfortumab vedotin-ejfv EV-302 Trial PADCEV pembrolizumab

2023年09月22日

Evopoint Announces Clinical Trial Collaboration Agreement with MSD for the Study of XNW5004 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

Evopoint Announces Clinical Trial Collaboration Agreement with MSD for the Study of XNW5004 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Solid Tumors

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Evopoint Announces Clinical Trial Collaboration Agreement with in Advanced Solid Tumors pembrolizumab

2023年04月06日

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer pembrolizumab Seagen with KEYTRUDA

2022年12月20日

Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

その他ヘルスバイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験　 TimeLine: Early-Stage Triple-Negative Breast Cancer Including in High-Risk Merck’s KEYTRUDA pembrolizumab TNBC

2022年09月27日

Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA® (pembrolizumab)

Qurient Announces Collaboration Agreement with MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA® (pembrolizumab)

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: MSD to Evaluate Selective CDK7 Inhibitor Q901 in Combination With KEYTRUDA pembrolizumab Qurient Announces Collaboration Agreement with

2022年09月15日